BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 27868287)

  • 21. Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
    Hamai Y; Hihara J; Taomoto J; Yamakita I; Ibuki Y; Okada M
    World J Surg; 2014 Aug; 38(8):2046-51. PubMed ID: 24615604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging
    Beukinga RJ; Hulshoff JB; Mul VEM; Noordzij W; Kats-Ugurlu G; Slart RHJA; Plukker JTM
    Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy.
    Fang HY; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27878893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy.
    Wen J; Luo K; Liu H; Liu S; Lin G; Hu Y; Zhang X; Wang G; Chen Y; Chen Z; Li Y; Lin T; Xie X; Liu M; Wang H; Yang H; Fu J
    Ann Surg; 2016 May; 263(5):942-8. PubMed ID: 26445467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Nomogram for Thoracic Esophageal Squamous Cell Carcinoma after Radical Esophagectomy.
    Su D; Zhou X; Chen Q; Jiang Y; Yang X; Zheng W; Tao K; Wu J; Yan Z; Liu L; Wu S; Mao W
    PLoS One; 2015; 10(4):e0124437. PubMed ID: 25893524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
    Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
    Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
    Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
    Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with false-negative endoscopic biopsy results after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Yeh CJ; Lee MH; Wen YW; Chang HK; Tseng CK; Liu YH
    Medicine (Baltimore); 2015 Feb; 94(8):e588. PubMed ID: 25715265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery.
    Shapiro J; van Klaveren D; Lagarde SM; Toxopeus EL; van der Gaast A; Hulshof MC; Wijnhoven BP; van Berge Henegouwen MI; Steyerberg EW; van Lanschot JJ
    Br J Surg; 2016 Jul; 103(8):1039-47. PubMed ID: 27115731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yang Z; He B; Zhuang X; Gao X; Wang D; Li M; Lin Z; Luo R
    J Radiat Res; 2019 Jul; 60(4):538-545. PubMed ID: 31111948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.
    Wu Y; Chen J; Zhao L; Li Q; Zhu J; Yang H; Guo S; Xi M
    Cancer Res Treat; 2021 Jan; 53(1):172-183. PubMed ID: 32898941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy.
    Deng W; Zhang W; Yang J; Ni W; Yu S; Li C; Chang X; Zhou Z; Chen D; Feng Q; Chen X; Lin Y; Zhu K; Zheng X; He J; Gao S; Xue Q; Mao Y; Cheng G; Sun K; Liu X; Fang D; Chen J; Xiao Z
    Ann Surg Oncol; 2019 Sep; 26(9):2890-2898. PubMed ID: 31183641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Chemoradiation Versus Upfront Esophagectomy in Clinical Stage II and III Esophageal Squamous Cell Carcinoma.
    Hsu PK; Chen HS; Liu CC; Wu SC
    Ann Surg Oncol; 2019 Feb; 26(2):506-513. PubMed ID: 30430325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer.
    Zhang JL; Wang HY; Yang Q; Lin SY; Luo GY; Zhang R; Xu GL
    World J Gastroenterol; 2015 Apr; 21(14):4240-7. PubMed ID: 25892874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.